Publications by authors named "Robert Ireton"
Article Synopsis
- Patients with atrial fibrillation (AF) often struggle with understanding their treatment options for stroke prevention, prompting the need for better decision-making tools.
- A trial using an Atrial Fibrillation Shared Decision Making Tool (AFSDM) with 76 patients showed significant improvements in their knowledge about AF, decreased confusion regarding treatment decisions, and higher satisfaction with their care team.
- The results indicated that after using the AFSDM, decisional conflict decreased, satisfaction scores increased, knowledge about AF and risks improved, and medication adherence was notably enhanced.
Background: Appropriate thromboprophylaxis for patients with atrial fibrillation or atrial flutter (AF) remains a national challenge. The recent availability of direct oral anticoagulants (DOACs) with comparable efficacy and improved safety compared with warfarin alters the balance between risk factors for stroke and benefit of anticoagulation. Our objective was to examine the impact of DOACs as an alternative to warfarin on the net benefit of oral anticoagulant therapy (OAT) in a real-world population of AF patients.
View Article and Find Full Text PDFBackground: Appropriate thromboprophylaxis for patients with atrial fibrillation (AF) remains a national challenge.
Methods: We hypothesized that provision of decision support in the form of an Atrial Fibrillation Decision Support Tool (AFDST) would improve thromboprophylaxis for AF patients. We conducted a cluster randomized trial involving 15 primary care practices and 1,493 adults with nonvalvular AF in an integrated health care system between April 2014 and February 2015.
Objectives: To assess the appropriateness of oral anticoagulant therapy (OAT) in women and elderly adults, looking for patterns of undertreatment or unnecessary treatment.
Design: Retrospective cohort study.
Setting: Primary care practices of an academic healthcare system.
Background: Guidelines for anticoagulant therapy in patients with atrial fibrillation are based on stroke risk as calculated by either the CHADS2 or the CHA2DS2VASc scores and do not integrate bleeding risk in an explicit, quantitative manner. Our objective was to quantify the net clinical benefit resulting from improved decision making about antithrombotic therapy.
Methods And Results: This study is a retrospective cohort study of 1876 adults with nonvalvular atrial fibrillation or flutter seen in primary care settings of an integrated healthcare delivery system between December 2012 and January 2014.